In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hannah Daniel

Reporter

Hannah joined Medtech Insight from HBW Insight in August 2022 and reports on cybersecurity, patent law and other facets of medical device regulation. Hannah is passionate about the intersection of science and communication and holds a bachelor’s degree in biology from Carnegie Mellon University.

Latest From Hannah Daniel

Medtech Advocate Announces Retirement From House Of Representatives

Medical device advocate Anna Eshoo has announced that she plans to retire from Congress after three decades.

Politics Policy

Report: HDO Mutual Aid Can Provide Legacy Device Security

A report from MITRE recommends mutual aid partnerships between large and small HDOs to secure legacy medical devices.

Cybersecurity Regulation

Policy Misalignment Is Harming AI Development, Experts Say

Experts lamented the lack of consensus standards for AI medical devices, which they said could pose harm to innovators.

Artificial Intelligence Policy

‘We Need To Be Transparent About Our Failures,’ Experts Say About AI Development

 Stakeholders discussed the need for transparency and explainability of AI models at the AI Summit in Cincinnati. 

Artificial Intelligence Regulation

AI Can Be A ‘Catalyst’ For Device Cybersecurity

Cybersecurity expert Seth Carmody explained how artificial intelligence can assist reviewers and developers in advancing device cybersecurity.

Artificial Intelligence Regulation

News We’re Watching: More Class I Recalls, FDA Expands TAP, Guardant Appeals Patent Verdict, And More

This week, the US FDA labelled several recalls class I, approved an at-home diagnostic for chlamydia and gonorrhea, and announced the expansion of its TAP pilot program. Guardant Health also announced it would appeal a verdict in a patent suit against the company and AdvaMed voiced its continued support for pending breakthrough device legislation.

News We're Watching FDA
See All
UsernamePublicRestriction

Register